About Sickkids
About SickKids

R. Maarten Egeler, MD, PhD

The Hospital for Sick Children
Section Head Stem Cell Transplantation
Haematology/Oncology

Research Institute
Senior Associate Scientist
Developmental & Stem Cell Biology

University of Toronto
Professor
Paediatrics


Phone: 416-813-7654 ext. 202349
e-mail: maarten.egeler@sickkids.ca

Brief Biography

Professor Maarten Egeler is an internationally recognized expert in the treatment and research of stem cell transplantation, histiocytoses, and bone tumours. After graduation in 1985 from the University of Leiden, and his residency in paediatrics in Amsterdam, the Netherlands, he was awarded a research fellowship from the Royal Dutch Academy of Arts and Sciences at the University of Minnesota, where he worked on his PhD thesis titled: Langerhans cell histiocytoses and other histiocytic disorders, successfully defended in 1993.

Subsequently he joined the Division of Pediatric Hematology and Oncology at the Erasmus University of Rotterdam, and after five years he was appointed Associate Professor of Oncology and Pediatrics at the Southern Alberta Children's Cancer Program of the University of Calgary, Canada. In 2000, he became the Director of the Division of Pediatric Immunology, Hematology, Oncology, Bone Marrow Transplantation and Auto-immune disease at the Leiden University Medical Center. In 2011, he moved back to Canada and accepted the position of Section Head, Stem Cell Transplantation within the Division of Hematology and Oncology at The Hospital for Sick Children (SickKids) in Toronto. He is a holder of the Garron Family Chair in Childhood Cancer Research and a professor at the University of Toronto.

Dr. Egeler has served for a decade as Board Member of the Pediatric Diseases Working Party of the European Group for Blood and Marrow Transplantation (EBMT). He has been President of the International Society of Pediatric Oncology (SIOP), the President of the international Histiocyte Society (Board-member for 12 years), and President of the Dutch Childhood Oncology Group (DCOG) (active Board-member for 10 years). Currently he is active within the Oncology Disorders Strategy Group and the Cellular Therapeutic Strategy Group of the Pediatric Blood and Marrow Transplant Consortium (PBMTC).

His research has been dedicated to Stem Cell Transplantation with a main focus on Graft-versus-Host Disease opposed to Graft-versus Leukemia and mesenchymal stem cells. He considers Stem Cell Transplantation the platform for cell therapy and innovation. Furthermore, he has great interest and expertise in the immunologic aspects of dendritic cells in relation to Langerhans cell histiocytoses. Cell Therapy (NK Cell Therapy) against paediatric brain tumours is his third field of interest.

Dr. Egeler has authored and co-authored more than 260 manuscripts and chapters in national and international journals, with highlights in Blood, Journal of Experimental Medicine, Nature Reviews and Nature Medicine. He is still mentoring ten PhD students at the University of Leiden, but will develop something similar at SickKids.

Research Interests

  • Cell and Immunotherapy (post Stem Cell Transplantation)
  • Dendritic Cell Biology (in Langerhans cell histiocytosis)
  • Cell Therapy (NK Cell Therapy) against paediatric brain tumours

External Funding

Over 10 million dollars in the last 20 years.

Publications

For a complete list of publications, please see PubMed

Anninga JK, Gelderblom H, Fiocco M, Kroep JR, Taminiau AHM, Hogendoorn PCW, Egeler RM. (2011) Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand? European Journal of Cancer. 47:2431-2445.

Egeler RM, van Halteren AGM, Hogendoorn PCW, Laman JD, Leenen PJM. (2010) Langerhans cell histiocytosis; fascinating dynamics of the dendritic cell – macrophage lineage.  Immunological Reviews. 234:213-232.

Da Costa CET, Szuhai K, van Eijk R, Hoogeboom M, Sciot R, Mertens F, Björgvinsdóttir H, Debiec-Rychter M, de Krijger RR, Hogendoorn PCW, Annels NE, Egeler RM. (2009) No genomic aberrations in Langerhans cell histiocytosis as assessed by diverse molecular technologies.  Genes, Chromosomes & Cancer. 48:239-249. 

Le Blanc K, Frassoni F, Ball LM, Locatelli F, Roelofs H, Lewis I, Lanino E, Sundberg B, Bernardo ME, Remberger M, Dini G, Egeler RM, Bacigalupo A, Fibbe WE, Ringden O. (2008) Mesenchymal stem cells for treatment of severe, refractory acute Graft-versus-Host Disease.  Lancet. 371:1579-1586. 

Coury F, Annels N, Rivollier A, Olsson S, Santoro A, Speziani C, Azocar O, Flacher M, Djebali S, Tebib J, Brytting M, Egeler RM, Rabourdin-Combe C, Henter JI, Arico M, Delprat C. (2008) Langerhans cell histiocytosis reveals a novel IL-17A-dependent pathway of dendritic cell fusion.  Nature Medicine. 14:81-87. 

Ball LM, Bernardo ME, Roelofs H, Lankester AC, Cometa A, Egeler RM, Locatelli F, Fibbe WE. (2007) Co-transplantation of ex vivo expanded mesenchymal stem cells accelerate lymphocyte recovery and may reduce the risk of graft failure in haplo-identical hematopoietic stem cell transplantation. Blood. 110: 2764-2767. 

da Costa CET, Annels NE, Faaij CMJM, Forsyth RG, Hogendoorn PCW, Egeler RM. (2005) Presence of osteoclast-like multinucleated giant cells in the bone and nonostotic lesions of Langerhans cell histiocytosis.  Journal of Experimental Medicine. 201:687-693. 
 

Beverley PCL, Egeler RM, Arceci RJ, Pritchard J.  (2005) The Nikolas Symposia and Histiocytosis. Nature Reviews Cancer. 5:488-494. 

Anninga JK, van de Vijver MJ, Cleton-Jansen A-M, Kristel PMP, Taminiau AHM, Nooij M, Egeler RM, Hogendoorn PCW. (2004) Overexpression of the HER-2 oncogene does not play a role in osteosarcomas.  European Journal of Cancer. 40:963-970. 

Annels NE, da Costa CET, Prins FA, Willemze A, Hogendoorn PCW, Egeler RM. (2003) Aberrant chemokine receptor expression and chemokine production by Langerhans cells underlies the pathogenesis of Langerhans cell histiocytosis. Journal of Experimental Medicine. 197: 1385-1390. 

Laman JD, Leenen PJM, Annels NE, Hogendoorn PCW, Egeler RM. (2003) Langerhans cell histiocytosis; “insight in dendritic-cell biology”.  Trends in Immunology. 24:190-196. 

Egeler RM, Favara BE, Laman JD, Claassen E. (2000) Abundant expression of CD40 and CD40-ligand (CD154) in paediatric Langerhans cell histiocytosis lesions.  European Journal of Cancer. 36:2105-2110. 

Egeler RM, Favara BE, van Meurs M, Laman JD, Claassen E. (1999) Differential in situ cytokine profiles of Langerhans-like cells and T-cells in Langerhans cell histiocytosis: abundant expression of cytokines relevant to disease and treatment.  Blood. 94:4195-4201.